Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 1997

View Archived Issues

New cardiotonic agent reported by Japanese academics

Rogaine Extra Strength approved by FDA as OTC

Cell Genesys issued U.S. patent for gene therapy

Complement activation inhibitors prepared at U of Pennsylvania

Scripps prepares MCBI analogues of antitumor antibiotics

rhIL-10 evaluated for safety and efficacy in RA patients

Basiliximab reduces renal allograft rejection in phase III trial

rhIL-11 effective in rats with adjuvant arthritis

Ibex issued U.S. patent for recombinant heparinase

Potential new antiatherosclerotic agent discovered at Tanabe Seiyaku

Sankyo and ArQule enter drug discovery collaboration

rhIGF-I + insulin combination tested in adolescents with IDDM

Sch-207278: new protein farnesyltransferase inhibitor of microbial origin

Kyowa Hakko's UCT-1072M1, a new antitumor antibiotic

BCH-1393 stimulates CTL response in vitro and in vivo

New VCAM-1 inhibitor isolated from marine sponge

BTG licenses peptide technology to CeNeS

New neurologic drugs from Nippon Kayaku

Banyu describes protein farnesyltransferase inhibitors

FDA clears Plavix

Modex Therapeutiques established as independent company; CytoTherapeutics reduces ownership

Sankyo isolates A-76356, novel antibacterial agent

New antifungals from Pola

Alza and SmithKline Beecham expand Nicoderm marketing agreement

Ono discloses novel NOS inhibitors with broad potential application

Centocor's anti-TNF-alpha antibody closes fistulae in Crohn's patients

AMBI cleared by FDA to commence nisin trials

Idec begins phase I/II trial for 9-AC

New laxative proves safe and effective for short-term treatment of constipation

L-Arginine safe and effective in spastic esophageal motor disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 11, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...